Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564142 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
A Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- Active
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT06564142 is a Phase 3 study of Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Alpine Immune Sciences Inc, A Subsidiary of Vertex. The registered enrollment target is 605 participants, above the 258-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (134% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06564142, a Phase 3 study of Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Conditions Studied
Interventions
- DRUG Povetacicept
- DRUG Placebo (matched to Povetacicept)
Study Locations (20)
California
- West Coast Kidney - Fremont
- The Medical Research Group, Inc. (FRENOVA) - Fresno
- CARE Institute - Carabello Kidney - Los Angeles
- Providence Medical Foundation - Orange - Orange
- National Nephrology Alliance Research - Riverside
- UC Davis Health - Sacramento
- Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- University of California San Francisco (UCSF) - San Francisco
Florida
- South Florida Nephrology Group PA, Research Div. - Coral Springs
- Dolphin Medical Research - Doral
- Nephrology Associates of Central Florida - Hollywood
- Tectum Medical Research, LLC - Hollywood
- South Florida Research Institute - Lauderdale Lakes
- Florida Kidney Physicians - Melbourne - Melbourne
Arizona
- Arizona Kidney Disease and Hypertension Center - Thomas Office - Phoenix
- Arizona Kidney Disease and Hypertension Center - Tuscon - Tucson
Colorado
- Western Nephrology - Arvada
- Colorado Kidney Care - Denver
Alabama
- Apogee Clinical Research, LLC - Huntsville
Delaware
- Nephrology Associates Delaware Kidney (FRENOVA) - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06564142
The ClinicalTrials.gov registry entry for NCT06564142 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 258-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (134% higher). The listed sponsor is Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Povetacicept is the first listed.
NCT06564142 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06564142 about?
NCT06564142 is a clinical study titled "Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)". The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
What is the current status of trial NCT06564142?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2024-08-30. Estimated completion is 2028-01-30.
What conditions does trial NCT06564142 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.
What interventions are being tested in trial NCT06564142?
The interventions under investigation include: Povetacicept (DRUG), Placebo (matched to Povetacicept) (DRUG).
Who is sponsoring clinical trial NCT06564142?
This trial is sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564142 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.